Elevation Oncology, Inc. - Common Stock, par value $0.0001 per share (ELEV)

Historical Holders from Q2 2021 to Q3 2025

Type / Class
Equity / Common Stock, par value $0.0001 per share
Symbol
ELEV
Shares outstanding
62,337,402
Price per share
$0.3600
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares as of 30 Sep 2025
2,000
Total reported value
$720
Share change
-29,532,288
Value change
-$10,839,974
Avg sell value change
-0%
Number of holders
1
Price from insider filings
$0.3600
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Elevation Oncology, Inc. - Common Stock, par value $0.0001 per share (ELEV) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
BIOTECHNOLOGY VALUE FUND L P 7% $1,642,800 4,440,000 BVF PARTNERS L P/IL 31 Mar 2025
TANG CAPITAL MANAGEMENT LLC 5% -50% $1,183,700 -$1,112,990 3,115,000 -48% TANG CAPITAL MANAGEMENT, LLC 30 Jun 2025
VANGUARD GROUP INC 4.4% $965,717 2,610,045 The Vanguard Group 31 Dec 2024
GOLDMAN SACHS GROUP INC 2.8% $622,842 1,683,356 THE GOLDMAN SACHS GROUP, INC. 31 Dec 2024
BlackRock, Inc. 0.6% -96% $135,478 -$1,025,726 369,048 -88% BlackRock, Inc. 30 Jun 2025
As of 30 Sep 2025, Elevation Oncology, Inc. - Common Stock, par value $0.0001 per share (ELEV) has 1 institutional shareholder filing 13F forms. They hold 2,000 shares. of 62,337,402 outstanding shares (0%) .

Institutional Holders of Elevation Oncology, Inc. - Common Stock, par value $0.0001 per share (ELEV) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (% of par) Investors
2025 Q3 2,000 $720 -$10,839,974 36% 1
2025 Q2 29,539,370 $10,842,560 -$793,553 36.71% 62
2025 Q1 33,845,637 $8,763,416 -$4,443,040 25.91% 70
2024 Q4 39,972,031 $22,485,572 -$3,751,363 56.26% 70
2024 Q3 45,935,957 $27,556,513 -$42,322,821 59.99% 67
2024 Q2 52,117,516 $140,353,793 +$17,122,980 270% 79
2024 Q1 43,980,695 $225,620,623 +$110,373,555 513% 61
2023 Q4 25,848,863 $13,880,951 -$1,444,451 53.7% 31
2023 Q3 28,047,314 $18,583,583 -$5,577,531 66.26% 40
2023 Q2 31,537,990 $48,818,036 +$22,972,167 152% 38
2023 Q1 16,241,361 $30,858,572 +$3,765,785 190% 27
2022 Q4 14,423,778 $13,696,323 +$91,721 95% 26
2022 Q3 14,278,557 $16,134,000 -$1,527,236 112.99% 21
2022 Q2 15,368,572 $21,517,000 -$7,037,226 140.02% 24
2022 Q1 18,712,566 $47,158,000 +$631,515 251.99% 28
2021 Q4 15,932,443 $95,906,000 -$3,116,582 601.99% 33
2021 Q3 15,882,998 $123,294,000 -$8,545,986 778.98% 21
2021 Q2 16,192,115 $217,244,000 +$217,244,000 1,356.98% 35